STATIN-ASSOCIATED INTOLERANCE AND ITS PREVENTION.

The review analyzes the literature data, which covers the intolerance of statins associated with myopathy. The article gives a definition of statin intolerance, analyzed data from a randomized, controlled trials, where are indicated frequency of statin-associated myopathy, its symptoms in juxtaposition with an increase in creatine kinase activity. It is noted that the frequency of complications depends on the applied statin, its dose, duration, the use of other risk factors that contribute to the development of myopathy.

[Treatment of nonalcogolic fatty disease of liver].

The experimental and clinical data concerning of treatment of nonalcogolic fatty liver disease (NAFLD) are summarized and analyzed in the review. Some aspects of pathogenetic pharmacotherapy of NAFLD have been discussed (correction of insulin resistance, obesity, dislipidemia, oxidative stress, hepatoprotectors, restoration of intestine microbiosis, replacement hormonal, syndrome and antihypertensive drugs). Medical and non - medical methods of treatment is compared.

[Peculiarities of metabolic syndrome and nonalcogolic fatty liver disease in menopausal women].

Correlation between menopause metabolic syndrome and nonalcogolic fatty liver disease (NAFLD) is reviewed. NAFLD refers to a wide spectrum of liver disease ranging from simple fatty liver (steatosis), to nonalcoholic steatohepatitis, to cirrhosis. The causes and pathogenetic factors of the disease are still under investigation.

[Changes of metabolic indices caused by berberin and extract, obtained from the bark of Phellodendron lavalei, introduced in subtropic regions of Georgia, in streptozotocin induced diabetic rats].

The goal of the study was to identify changes in lipid metabolism, functional condition of liver and kidney influenced by berberin and extract, obtained from the bark of Рhеllodendron lavalei, introduced in sub tropic regions of Georgia, in streptozotocin induced diabetic rats. Diabetes in animals was induced by single intraperitoneal injection of streptozotocin in 1 M citrate buffer, pH 4.5, dose 40 mg/kg per body weight, 1 ml volume.

[Pharmacotherapy and prevention of osteoporosis].

In the article data regarding pharmacological prevention of primary osteoporosis is reviewed. Some main aspects of the disease are underlined. The primary prevention of osteoporosis is targeted on building up and sustaining the strength of the skeleton during different periods of human life.